Dr. Tim Garnett

Chief Medical Officer and Senior Vice President, Medicines Development

Unit & Lilly Research Laboratories

Dr. Timothy Garnett, MBBS, FRCOG, is Chief Medical Officer, Senior Vice-President and Co-
Leader of the Medicines Development Unit managing Medical Affairs, Medical Strategy and Development, Global Patient Outcomes and Real World Evidence, Global Regulatory, Global Patient Safety, Clinical Development in China and Japan, and Early Phase Medicine for Eli Lilly and Company.

During his 18 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director – Duloxetine SUI Team; and European Clinical Research Physician for EVISTA.

Prior to joining Lilly, Dr. Garnett had acquired 7 years of experience, holding a variety of positions in the pharmaceutical industry in Europe with Organon Laboratories. He graduated in Medicine at St. George’s Hospital in London. He practiced Obstetrics and Gynecology for eight years prior to joining the pharmaceutical industry and conducted clinical research into menopause, pre-menstrual tension and post-menopausal osteoporosis.

Dr. Garnett is a Fellow of the Royal College of Obstetricians and Gynecologists in the United Kingdom. He is also an active board member for the following: Centre for Innovation in Regulatory Science; Personalized Medicine Coalition; Indiana Health Industry Forum; Eiteljorg Museum of American Indians and Western Art; and WFYI Public Broadcasting.